Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Allison Wood

Gastroenterology Lansing, MI Doctor of Osteopathy

NPI 1649438318 CMS profile 346710

1515 Lake Lansing Rd, Ste O, Lansing, MI 48912

Open in the dashboard

General payments

$8,801

460 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Allison Wood of Lansing, MI is reported in the CMS Open Payments database as having received $8,801 across 460 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,276 88
2024 General $2,243 110
2023 General $2,095 130
2022 General $744 42
2021 General $119 8
2020 General $78 4
2019 General $1,247 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allison Wood
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Allison Wood were reported at $2,276. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Allison Wood Gastroenterology median Middle half National median
2019 $1,247 $417 $126–$1,100 $163
2020 $78 $224 $74–$624 $114
2021 $119 $352 $106–$1,054 $132
2022 $744 $448 $129–$1,270 $149
2023 $2,095 $533 $150–$1,390 $160
2024 $2,243 $605 $160–$1,606 $164
2025 $2,276 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,891 85 payments
  2. Janssen Biotech, Inc. $1,231 55 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $787 51 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $676 60 payments
  5. Pfizer Inc. $599 32 payments
  6. Nestle HealthCare Nutrition Inc. $386 27 payments
  7. Ardelyx, Inc. $358 19 payments
  8. Lilly USA, LLC $308 11 payments
  9. Regeneron Healthcare Solutions, Inc. $265 10 payments
  10. Celgene Corporation $237 23 payments
  11. Other $2,064 87 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,312 447 payments
  2. Education $489 13 payments
Products named General payments · program years 2019–2025
  1. STELARA $872 43 payments
  2. RINVOQ $715 39 payments
  3. SKYRIZI Immunology $702 26 payments
  4. VELSIPITY $567 30 payments
  5. SIMPONI $541 30 payments
  6. XIFAXAN $534 48 payments
  7. SKYRIZI Immunology $524 20 payments
  8. ZENPEP $524 33 payments
  9. TREMFYA $520 16 payments
  10. SIMPONI ARIA $485 23 payments
  11. Other $5,708 311 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

1,266

Median for Gastroenterology: 569

Drug cost

$1,919,444

Median for Gastroenterology: $104,976

Branded share of claims

49.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 23 $616,905
Gattex Teduglutide Brand 11 $501,819
Zenpep Lipase/Protease/Amylase Brand 28 $154,006
Xifaxan Rifaximin Brand 47 $146,562
Humira(Cf) Pen Adalimumab Brand 12 $113,089
Rezdiffra Resmetirom Brand 21 $82,358
Linzess Linaclotide Brand 67 $80,977
Creon Lipase/Protease/Amylase Brand 12 $39,973
Mesalamine Generic 27 $31,831
Ibsrela Tenapanor Hcl Brand 18 $29,978

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$34,989

Medicare's payments for the services billed

Medicare patients

194

Average age 72

Services billed

367

137 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 48%
Chronic kidney disease 28%
Depression 28%
Diabetes 27%
Ischemic heart disease 23%
Cancer 22%
Osteoporosis 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VELSIPITY
  • PFIZER INC. $253
$253 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $173
$173 — —
OMVOH
  • Lilly USA, LLC $169
$169 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $154
$154 47 —
STELARA
  • Janssen Biotech, Inc. $132
$132 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

460 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record